Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expanded Access Programs Need FDA Policy Changes To Really Expand

Executive Summary

Agency should issue statement that deaths occurring during compassionate use will not automatically penalize a drug's development, ethicists from NYU Langone Medical Center say.


Related Content

Expanded Access Programs Eyed For Data-Gathering Purposes
Moscicki, One Of US FDA's Industry Connections, Moves To PhRMA
Reagan-Udall Expanded Access Navigator Ready To Launch
'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On
'Right To Try' Bill Contradicts US FDA’s Mission, Former Official Says
FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide
Making Expanded Access Programs Work For - Not Against - Your Trial Drug


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts